Nucleic acid drugs for prevention of cardiac rejection

Journal of Biomedicine and Biotechnology

Volumn 2009, Issue , 2009, Pages

  Suzuki, Jun Ichi ^a   Isobe, Mitsuaki ^b   Morishita, Ryuichi ^c   Nagai, Ryozo ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLIN DEPENDENT KINASE 2; DOUBLE STRANDED DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEIC ACID; PROTEIN BCL X; STAT1 PROTEIN; TRANSCRIPTION FACTOR E2F; ANTISENSE OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE;

ARTICLE; CHRONIC GRAFT REJECTION; GENE CONTROL; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEART TRANSPLANTATION; HUMAN; NONHUMAN; ANIMAL; GRAFT REJECTION; REVIEW;

ANIMALS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; NUCLEIC ACIDS; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE;

EID: 75149140485     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2009/916514     Document Type: Article

References (42)

1. Taylor D. O., Edwards L. B., Aurora P., Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report-2008 Journal of Heart and Lung Transplantation 2008 27 9 943 956
2. Mitchell R. N., Graft vascular disease: immune response meets the vessel wall Annual Review of Pathology 2009 4 19 47
3. Suzuki J., Isobe M., Aikawa M., Nonmuscle and smooth muscle myosin heavy chain expression in rejected cardiac allografts: a study in rat and monkey models Circulation 1996 96 5 1118 1124
4. Tellides G., Pober J. S., Interferon-axis in graft arteriosclerosis Circulation Research 2007 100 5 622 632
5. Morishita R., Gibbons G. H., Ellison K. E., Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides Journal of Clinical Investigation 1994 93 4 1458 1464
6. Morishita R., Aoki M., Ogihara T., Does gene therapy become pharmacotherapy? Experimental Physiology 2005 90 3 307 313
7. Morishita R., Perspective in progress of cardiovascular gene therapy Journal of Pharmacological Sciences 2004 95 1 1 8
8. Nakagami H., Tomita N., Kaneda Y., Ogihara T., Morishita R., Anti-oxidant gene therapy by NF B decoy oligodeoxynucleotide Current Pharmaceutical Biotechnology 2006 7 2 95 100
9. Tsai L. H., Harlow E., Meyerson M., Isolation of the human cdk2 gene that encodes the cycline A and adenovirus E1A associated p33 kinase Nature 1991 353 174 177
10. Koff A., Otsuki M., Polyak K., Roberts J. M., Massague J., Negative regulation of G1 in mammalian cells: inhibition of cycline E-dependent kinase by TGF-beta Science 1993 260 536 539 (Pubitemid 23161617)
11. Suzuki J., Isobe M., Morishita R., Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide Nature Medicine 1997 3 8 900 903
12. Schwartz S. M., Reidy M. A., OBrien E. R., Assessment of factors important in atherosclerotic occlusion and restenosis Thrombosis and Haemostasis 1995 74 1 541 551
13. Morishita R., Gibbons G. H., Ellison K. E., Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia Proceedings of the National Academy of Sciences of the United States of America 1993 90 18 8474 8478
14. Suzuki J., Isobe M., Morishita R., Nishikawa T., Amano J., Kaneda Y., Prevention of cardiac allograft arteriosclerosis using antisense proliferating-cell nuclear antigen oligonucleotide Transplantation 2000 70 2 398 400
15. Geng Y. J., Libby P., Evidence for apoptosis in advanced human atheroma: colocalization with interleukin-1-converting enzyme American Journal of Pathology 1995 147 2 251 266
16. Golstein P., Controlling cell death Science 1997 275 5303 1081 1082
17. Gajewski T. F., Thompson C. B., Apoptosis meets signal transduction: elimination of a BAD influence Cell 1996 87 4 589 592
18. Pollman M. J., Hall J. L., Mann M. J., Zhang L., Gibbons G. H., Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease Nature Medicine 1998 4 2 222 227
19. Suzuki J., Isobe M., Morishita R., Nishikawa T., Amano J., Kaneda Y., Antisense bcl-x oligonucleotide induces apoptosis and prevents arterial neointimal formation in murine cardiac allografts Cardiovascular Research 2000 45 3 783 787
20. Pagano M., Draetta G., Durr J., Association of cdk2 kinase with the transcription factor E2F during S phase Science 1992 255 5048 1144 1147
21. Weintraub S. J., Prater C. A., Dean D. C., Retinoblastoma protein switches the E2F site from positive to negative element Nature 1992 358 6383 259 261
22. Morishita R., Gibbons G. H., Horiuchi M., A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo Proceedings of the National Academy of Sciences of the United States of America 1995 92 13 5855 5859
23. Kawauchi M., Suzuki J., Morishita R., Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates Circulation Research 2000 87 11 1063 1068
24. May M. J., Ghosh S., Signal transduction through NF-B Immunology Today 1998 19 2 80 88
25. Sha W. C., Regulation of immune responses by NF-B/Rel transcription factor The Journal of Experimental Medicine 1998 187 143 146
26. Barnes P. J., Karin M., Nuclear factor-B: a pivotal transcription factor in chronic inflammatory diseases The New England Journal of Medicine 1997 336 15 1066 1071
27. Suzuki J., Morishita R., Amano J., Kaneda Y., Isobe M., Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts Gene Therapy 2000 7 21 1847 1852
28. Roebuck K. A., Finnegan A., Regulation of intercellular adhesion molecule-1 (CD54) gene expression Journal of Leukocyte Biology 1999 66 6 876 888
29. Jaruga B., Hong F., Kim W. H., Gao B., IFN-gamma/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1 American Journal of Physiology 2004 287 G1044 G1052
30. Hlschermann H., Stadlbauer T. H., Wagner A. H., STAT-1 and AP-1 decoy oligonucleotide therapy delays acute rejection and prolongs cardiac allograft survival Cardiovascular Research 2006 71 3 527 536
31. Stadlbauer T. H., Wagner A. H., Hlschermann H., AP-1 and STAT-1 decoy oligodeoxynucleotides attenuate transplant vasculopathy in rat cardiac allografts Cardiovascular Research 2008 79 4 698 705
32. Tomita N., Kashihara N., Morishita R., Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease Clinical and Experimental Nephrology 2007 11 1 7 17
33. Inagaki H., Suzuki J., Ogawa M., Taniyama Y., Morishita R., Isobe M., Ultrasound-microbubble-mediated NF-B decoy transfection attenuates neointimal formation after arterial injury in mice Journal of Vascular Research 2006 43 1 12 18
34. Koike H., Tomita N., Azuma H., A novel gene transfer method mediated by ultrasound and microbubbles into the kidney Journal of Gene Medicine 2005 7 1 108 116
35. Suzuki J., Ogawa M., Takayama K., Ultrasound-microbubble mediated ICAM-1 siRNA transfection attenuates neointimal formation after arterial injury in mice. Journal of the American College of Cardiology. In press
36. Mann M. J., Whittemore A. D., Donaldson M. C., Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial The Lancet 1999 354 9189 1493 1498
37. Alexander J. H., Hafley G., Harrington R. A., Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial Journal of the American Medical Association 2005 294 19 2446 2454
38. Suzuki J., Ito H., Gotoh R., Morishita R., Egashira K., Isobe M., Initial clinical cases of the use of a NF-B decoy at the site of coronary stenting for the prevention of restenosis Circulation Journal 2004 68 3 270 271
39. Egashira K., Suzuki J., Ito H., Aoki M., Isobe M., Morishita R., Long-term follow up of initial clinical cases with NF-B decoy oligodeoxynucleotide transfection at the site of coronary stenting Journal of Gene Medicine 2008 10 7 805 809
40. Suzuki J., Tezuka D., Morishita R., Isobe M., An initial case of suppressed restenosis with nuclear factor-kappa B decoy transfection after percutaneous coronary intervention Journal of Gene Medicine 2009 11 1 89 91
41. Morris M. J., Tong W. P., Cordon-Cardo C., Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer Clinical Cancer Research 2002 8 3 679 683
42. Cursiefen C., Bock F., Horn F. K., GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial Ophthalmology 2009 116 9 1630 1637